Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 15138201.
- Also identified by PMC identifier 1774089.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma.
Medical subject headings
- Antibodies, Monoclonal
- Crohn Disease
- Gastrointestinal Agents